Invitae Corporation (NVTA) Rating Lowered to Strong Sell at BidaskClub
BidaskClub lowered shares of Invitae Corporation (NYSE:NVTA) from a sell rating to a strong sell rating in a research note published on Wednesday.
NVTA has been the topic of a number of other research reports. Zacks Investment Research raised Invitae Corporation from a sell rating to a hold rating in a research note on Friday, August 11th. J P Morgan Chase & Co reissued an overweight rating and set a $15.00 price objective (up previously from $14.00) on shares of Invitae Corporation in a research note on Wednesday, August 9th. Finally, Leerink Swann lowered their price objective on Invitae Corporation from $14.00 to $12.00 and set an outperform rating on the stock in a research note on Tuesday, November 7th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company. Invitae Corporation currently has a consensus rating of Hold and a consensus price target of $13.50.
Invitae Corporation (NYSE NVTA) opened at $8.26 on Wednesday. The company has a debt-to-equity ratio of 0.33, a current ratio of 2.61 and a quick ratio of 4.39. Invitae Corporation has a 12 month low of $2.35 and a 12 month high of $8.46.
ILLEGAL ACTIVITY WARNING: This story was originally reported by Watch List News and is owned by of Watch List News. If you are accessing this story on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark legislation. The original version of this story can be read at https://www.watchlistnews.com/invitae-corporation-nvta-rating-lowered-to-strong-sell-at-bidaskclub/1713149.html.
Several institutional investors have recently made changes to their positions in NVTA. Verity Asset Management Inc. lifted its stake in shares of Invitae Corporation by 0.8% in the 2nd quarter. Verity Asset Management Inc. now owns 10,607 shares of the medical research company’s stock valued at $101,000 after purchasing an additional 81 shares during the last quarter. Lakeview Capital Partners LLC acquired a new position in shares of Invitae Corporation in the 3rd quarter valued at $117,000. Donald L. Hagan LLC lifted its stake in shares of Invitae Corporation by 30.0% in the 2nd quarter. Donald L. Hagan LLC now owns 13,000 shares of the medical research company’s stock valued at $124,000 after purchasing an additional 3,000 shares during the last quarter. Gabelli Funds LLC acquired a new position in shares of Invitae Corporation in the 3rd quarter valued at $131,000. Finally, State Board of Administration of Florida Retirement System acquired a new position in shares of Invitae Corporation in the 3rd quarter valued at $133,000. 58.00% of the stock is currently owned by institutional investors and hedge funds.
About Invitae Corporation
Invitae Corporation utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients.
Receive News & Ratings for Invitae Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invitae Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.